Investors & Media

Ionis reports third quarter 2023 financial results

Olezarsen Phase 3 data showed significant triglyceride lowering, substantial reductions in acute pancreatitis attacks and favorable safety and tolerability in patients with FCS ; on track for regulatory filings in early 2024 Eplontersen marketing applications accepted for review in the EU and

Read more
You are now leaving to visit